These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 20694695)

  • 1. Application of frontal affinity chromatography with mass spectrometry (FAC-MS) for stereospecific ligand-macromolecule interaction, detection and screening.
    Slon-Usakiewicz JJ; Redden P
    Methods Mol Biol; 2009; 572():219-30. PubMed ID: 20694695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frontal affinity chromatography with MS detection of the ligand binding domain of PPARγ receptor: ligand affinity screening and stereoselective ligand-macromolecule interaction.
    Calleri E; Fracchiolla G; Montanari R; Pochetti G; Lavecchia A; Loiodice F; Laghezza A; Piemontese L; Massolini G; Temporini C
    J Chromatogr A; 2012 Apr; 1232():84-92. PubMed ID: 22056242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Target-based drug discovery: the emerging success of frontal affinity chromatography coupled to mass spectrometry.
    Calleri E; Temporini C; Caccialanza G; Massolini G
    ChemMedChem; 2009 Jun; 4(6):905-16. PubMed ID: 19378293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frontal affinity chromatography with MS detection (FAC-MS) in drug discovery.
    Slon-Usakiewicz JJ; Ng W; Dai JR; Pasternak A; Redden PR
    Drug Discov Today; 2005 Mar; 10(6):409-16. PubMed ID: 15808820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Automated multiple ligand screening by frontal affinity chromatography-mass spectrometry (FAC-MS).
    Ng W; Dai JR; Slon-Usakiewicz JJ; Redden PR; Pasternak A; Reid N
    J Biomol Screen; 2007 Mar; 12(2):167-74. PubMed ID: 17218664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-throughput screening for enzyme inhibitors using frontal affinity chromatography with liquid chromatography and mass spectrometry.
    Ng ES; Yang F; Kameyama A; Palcic MM; Hindsgaul O; Schriemer DC
    Anal Chem; 2005 Oct; 77(19):6125-33. PubMed ID: 16194069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug screening of pharmaceutical discovery compounds by micro-size exclusion chromatography/mass spectrometry.
    Wabnitz PA; Loo JA
    Rapid Commun Mass Spectrom; 2002; 16(2):85-91. PubMed ID: 11754252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Applications of mass spectrometry in early stages of target based drug discovery.
    Deng G; Sanyal G
    J Pharm Biomed Anal; 2006 Feb; 40(3):528-38. PubMed ID: 16256286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A general technique to rank protein-ligand binding affinities and determine allosteric versus direct binding site competition in compound mixtures.
    Annis DA; Nazef N; Chuang CC; Scott MP; Nash HM
    J Am Chem Soc; 2004 Dec; 126(47):15495-503. PubMed ID: 15563178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frontal affinity chromatography coupled to mass spectrometry for screening mixtures of enzyme inhibitors.
    Zhang B; Palcic MM; Schriemer DC; Alvarez-Manilla G; Pierce M; Hindsgaul O
    Anal Biochem; 2001 Dec; 299(2):173-82. PubMed ID: 11730340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Capillary-scale frontal affinity chromatography/MALDI tandem mass spectrometry using protein-doped monolithic silica columns.
    Kovarik P; Hodgson RJ; Covey T; Brook MA; Brennan JD
    Anal Chem; 2005 May; 77(10):3340-50. PubMed ID: 15889927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frontal affinity chromatography in characterizing immobilized receptors.
    Calleri E; Temporini C; Massolini G
    J Pharm Biomed Anal; 2011 Apr; 54(5):911-25. PubMed ID: 21190807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Global kinase screening. Applications of frontal affinity chromatography coupled to mass spectrometry in drug discovery.
    Slon-Usakiewicz JJ; Dai JR; Ng W; Foster JE; Deretey E; Toledo-Sherman L; Redden PR; Pasternak A; Reid N
    Anal Chem; 2005 Mar; 77(5):1268-74. PubMed ID: 15732906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frontal affinity chromatography with MS detection of EphB2 tyrosine kinase receptor. 1. Comparison with conventional ELISA.
    Slon-Usakiewicz JJ; Ng W; Foster JE; Dai JR; Deretey E; Toledo-Sherman L; Redden PR; Pasternak A; Reid N
    J Med Chem; 2004 Oct; 47(21):5094-100. PubMed ID: 15456253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Native MS: an 'ESI' way to support structure- and fragment-based drug discovery.
    Vivat Hannah V; Atmanene C; Zeyer D; Van Dorsselaer A; Sanglier-Cianférani S
    Future Med Chem; 2010 Jan; 2(1):35-50. PubMed ID: 21426045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Affinity selection-mass spectrometry screening techniques for small molecule drug discovery.
    Annis DA; Nickbarg E; Yang X; Ziebell MR; Whitehurst CE
    Curr Opin Chem Biol; 2007 Oct; 11(5):518-26. PubMed ID: 17931956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frontal affinity chromatography-mass spectrometry.
    Ng ES; Chan NW; Lewis DF; Hindsgaul O; Schriemer DC
    Nat Protoc; 2007; 2(8):1907-17. PubMed ID: 17703202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Method for quantitative protein-ligand affinity measurements in compound mixtures.
    Annis DA; Shipps GW; Deng Y; Popovici-Müller J; Siddiqui MA; Curran PJ; Gowen M; Windsor WT
    Anal Chem; 2007 Jun; 79(12):4538-42. PubMed ID: 17500537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Weak affinity chromatography for evaluation of stereoisomers in early drug discovery.
    Duong-Thi MD; Bergström M; Fex T; Svensson S; Ohlson S; Isaksson R
    J Biomol Screen; 2013 Jul; 18(6):748-55. PubMed ID: 23479356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Advances in the study of affinity selection-ultrafiltration/HPLC-MS].
    Zhao HY; Zhang YZ; Xiao CL
    Yao Xue Xue Bao; 2009 Oct; 44(10):1084-8. PubMed ID: 20055128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.